Fc receptor-binding polypeptides with modified effector functions

US8546539B2 · kind B2 · utility

Assignee

• Novimmune SA · CH

Inventors

• Greg Elson · Saint-Julien-en-Genevois, FR
• Olivier Leger · Bonneville, FR

Key dates

• Filing date: May 14, 2008
• Grant date: Oct 1, 2013
• Expiry date: Apr 28, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/71
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.